Biotechnology Clinical Trials Regulatory Affairs Medical Research Genetic Engineering Patient Care Transplants Drug Development Vaccines Regulatory Affairs
Phase I/II results deliver a 91% overall response rate with mostly mild cytokine release syndrome alongside a larger international trial now underway